Return to Clinical Trials Search Results

A Phase 2/3, Open Label Randomized Study of Telisotuzumab Adizutecan Compared to Standard of Care in Subjects with Locally Advanced or Metastatic EGFR Mutated Non-Squamous Non-Small Cell Lung Cancer After Progression on a Third-Generation EGFR TKI - Andro

Primary Objectives: Phase 2: To evaluate the safety and tolerability of telisotuzumab adizutecan. To evaluate the efficacy of telisotuzumab as measured by objective response (OR) per blinded independent clinical review (BICR). To select the recommended phase 3 dose (RP3D) of telisotuzumab adizutecan. Phase 3: To evaluate the efficacy of telisotuzumab adizutecan compared with standard of care based on progression free survival (PFS) per BICR assessment.